CASP10

Summary

CASP10 (caspase 10, HGNC:1500) is a protein-coding gene on chromosome 2q33.1, encoding Caspase-10 (Q92851). Involved in the activation cascade of caspases responsible for apoptosis execution.

This gene encodes a protein which is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 3 and 7, and the protein itself is processed by caspase 8. Mutations in this gene are associated with type IIA autoimmune lymphoproliferative syndrome, non-Hodgkin lymphoma and gastric cancer. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 843 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autoimmune lymphoproliferative syndrome type 2A (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 6
• Clinical variants (ClinVar): 656 total — 5 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 93
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_032977

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1500
Approved symbol	CASP10
Name	caspase 10
Location	2q33.1
Locus type	gene with protein product
Status	Approved
Aliases	MCH4, FLICE-2
Ensembl gene	ENSG00000003400
Ensembl biotype	protein_coding
OMIM	601762
Entrez	843

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 12 protein_coding, 5 retained_intron, 2 nonsense_mediated_decay

ENST00000272879, ENST00000286186, ENST00000313728, ENST00000346817, ENST00000374650, ENST00000438843, ENST00000448480, ENST00000460140, ENST00000471191, ENST00000484926, ENST00000485408, ENST00000492363, ENST00000696190, ENST00000696191, ENST00000696199, ENST00000888473, ENST00000888474, ENST00000918539, ENST00000964672

RefSeq mRNA: 7 — MANE Select: NM_032977 NM_001206524, NM_001206542, NM_001230, NM_001306083, NM_032974, NM_032976, NM_032977

CCDS: CCDS2338, CCDS2339, CCDS2340, CCDS56159, CCDS56160, CCDS77506

Canonical transcript exons

ENST00000286186 — 10 exons

Exon	Start	End
ENSE00001131608	201205882	201205973
ENSE00001616411	201217588	201221665
ENSE00001896881	201183141	201183308
ENSE00001914382	201185771	201186124
ENSE00003479338	201195842	201195948
ENSE00003494616	201203730	201203766
ENSE00003541952	201187706	201187799
ENSE00003547008	201208075	201208183
ENSE00003582294	201192984	201193119
ENSE00003682151	201209070	201209562

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 90.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.9428 / max 252.9673, expressed in 1219 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24663	8.6108	1155
24662	1.0816	595
24661	0.2504	122

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
colonic epithelium	UBERON:0000397	90.08	gold quality
granulocyte	CL:0000094	88.95	gold quality
monocyte	CL:0000576	88.90	gold quality
leukocyte	CL:0000738	88.75	gold quality
mononuclear cell	CL:0000842	88.71	gold quality
rectum	UBERON:0001052	87.26	gold quality
buccal mucosa cell	CL:0002336	86.78	gold quality
spleen	UBERON:0002106	86.44	gold quality
bone marrow cell	CL:0002092	85.67	gold quality
blood	UBERON:0000178	84.30	gold quality
calcaneal tendon	UBERON:0003701	83.96	gold quality
upper lobe of left lung	UBERON:0008952	83.93	gold quality
upper lobe of lung	UBERON:0008948	82.88	gold quality
mucosa of transverse colon	UBERON:0004991	82.44	gold quality
apex of heart	UBERON:0002098	82.20	gold quality
duodenum	UBERON:0002114	82.14	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.82	gold quality
lower esophagus mucosa	UBERON:0035834	81.59	gold quality
small intestine	UBERON:0002108	81.25	gold quality
bone marrow	UBERON:0002371	80.99	gold quality
gall bladder	UBERON:0002110	80.93	gold quality
transverse colon	UBERON:0001157	80.91	gold quality
esophagus mucosa	UBERON:0002469	80.60	gold quality
vermiform appendix	UBERON:0001154	79.71	gold quality
omental fat pad	UBERON:0010414	79.58	gold quality
peritoneum	UBERON:0002358	79.52	gold quality
right lung	UBERON:0002167	79.45	gold quality
metanephros cortex	UBERON:0010533	79.37	gold quality
subcutaneous adipose tissue	UBERON:0002190	79.12	gold quality
lymph node	UBERON:0000029	78.92	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	344.72
E-ANND-3	yes	19.14
E-MTAB-8271	yes	8.68
E-GEOD-109979	no	202.78
E-MTAB-6075	no	119.49

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

133 targeting CASP10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4694-3P	99.79	69.53	2640

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• inactivating mutations in non-hodgkin lymphoma. (PMID:12010812)
• alteration associated with nodal metastasis in non-small cell lung cancer (PMID:12037669)
• Caspase-10 is recruited to & activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. Caspase-10 is cleaved during CD95-induced apoptosis of activated T cells. (PMID:12198154)
• histone H3 phosphoacetylation at the CASPASE-10 gene may play an important role in the induction of apoptosis in acute promyelocytic leukemia cells in response to arsenic trioxide (PMID:12388546)
• over-expression of GRB2 and FLICE2 in RA synovium is caused by TNF-alpha inducibility differentially regulated in RA synoviocytes and provide potential pathogenic roles of these genes in the hyperplasia of the RA synovium. (PMID:14687710)
• CASP10 levels are increased following DNA damage in a p53-dependent manner. (PMID:14688482)
• Re molecular requirements for neutrophil apoptosis: TNF-alpha-mediated apoptosis depends on the activation of caspase-8, spontaneous apoptosis requires the activation of caspase-10/b. (PMID:14761933)
• long-term inhibition of CARP expression results in suppression of cancer cell growth, highlighting their importance in tumor cell survival (PMID:15069192)
• taxol induces FADD-dependent apoptosis primarily through activation of caspase-10 but independently of death receptors (PMID:15452117)
• a model in which caspase-10 is a crucial component during TRAIL-mediated apoptosis (PMID:15767684)
• caspase-8 and -10, despite having overlapping functions, also have selective substrate cleavage specificities and might thereby exert nonredundant roles in apoptosis signaling (PMID:16186808)
• significant association seen between number of variant alleles I410 and H302 and highly decreased familial BC risk, pointing to interaction between CASP10 and CASP8 polymorphisms in breast carcinogenesis (PMID:16251207)
• Role of variants of caspase-10 in Autoimmune Lymphoproliferative Syndrome. (PMID:16446975)
• Altogether, these data indicate an active role for caspase-10 in cytotoxic drug-induced tumor cell death, downstream of the mitochondria. (PMID:16767158)
• These results suggest that caspase-10, DR-3 and IGFBP-3 are involved in apoptosis in the preeclamptic placenta. (PMID:17085968)
• identification of a novel function of HIPPI; it binds to specific upstream sequences of the caspase-1, caspase-8 and caspase-10 genes and alters the expression of the genes (PMID:17623017)
• A novel prodomain-only isoform of caspase-10 may preferentially play a regulatory role in NF-kappa B pathways. (PMID:17822854)
• Fas expression was reduced and caspase-10 activity was decreased in both patients (PMID:17999750)
• Multivariate logistic regression analysis revealed that CASP8 D302 H, CASP8 -652 6N del, and CASP10 I522L were independent risk factors for cutaneous melanoma. (PMID:18563783)
• Caspase-10 expression was down-regulated in both rectal adenomas and cancers (PMID:18716417)
• Single nucleotide polymorphism data suggest a role for CASP10 as a potential modifier of the asthma phenotype, specifically with measures of airway obstruction and bronchial hyperresponsiveness. (PMID:18823309)
• the effect of the ectopic expression of the human initiator caspases-10 in Saccharomyces cerevisiae (PMID:19166881)
• Results show that heat shock protein 90 beta is cleaved by activated caspase-10 under UVB irradiation. (PMID:19380486)
• Our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent. (PMID:19423537)
• Data show that the mDRA-6-induced apoptosis was repressed by 77.9% by Caspase-8 inhibitor ZIF, 54.2% by Caspase-3 inhibitor ZDF, and 8.7% by Caspase-9 inhibitor ZLF, but was not repressed by Caspase-10 inhibitor ZAF. (PMID:19550122)
• Data show that inhibition of NFAT3 activation by shNFAT3 significantly downregulated tumor necrosis factor (TNF)-alpha induction, its receptor TNFR1, caspase 10, caspase 3, and poly (ADP-ribose) polymerase. (PMID:19784808)
• Data show that caspase-10 is the most active caspase in apoptotic erythroid progenitors induced by 11 kDa and NS1 as well as during B19V infection. (PMID:19861680)
• CASP10 mutation might contribute to the pathogenesis of factions of T-acute lymphoblastic leukaemia and multiple myeloma. (PMID:19900088)
• Somatic mutation of CASP10 is rare in colon, breast, lung, and hepatocellular carcinomas. (PMID:20025484)
• Prx6 modulates TRAIL signaling as a negative regulator of caspase-8 and caspase-10 in death-inducing signaling complex formation of TRAIL-resistant metastatic cancer cells. (PMID:20829884)
• The CASP10 V410I polymorphism was not associated with breast or ovarian cancer risk for BRCA1 or BRCA2 mutation carriers. (PMID:20978178)
• Caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. (PMID:21368896)
• analysis of concerted antigen processing of a short viral antigen by human caspase-5 and -10 (PMID:21454616)
• Caspase-10 expression, measured by quantitative real-time RT-PCR, is a possible prognostic factor in patients with stage II colorectal cancer. (PMID:21559821)
• induces apoptosis in avian virus H5N1-infected human monocyte-derived macrophages (PMID:21911414)
• analysis of stoichiometry of the CD95 death-inducing signaling complex and demonstration of how procaspase-8, procaspase-10, and c-FLIP form DED chains at the DISC, enabling the formation of dimers and efficient activation of caspase-8 (PMID:22683265)
• The protein factor-arrest 11 (Far11) is essential for the toxicity of human caspase-10 in yeast and participates in the regulation of autophagy and the DNA damage signaling. (PMID:22782902)
• Genetic variations in CASP8 and CASP10 may act as potential predictive biomarkers for platinum-based chemotherapy toxicity in Chinese non-small cell lung cancer patients. (PMID:22843554)
• This meta-analysis suggests that the rs13006529 T carrier in the CASP-10 gene might be a risk factor for cancer susceptibility, especially for breast cancer. (PMID:23212337)
• Results found that polymorphisms of CASP9 and CASP10 genes may not contribute to CRC risk in Chinese population. (PMID:23303631)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	casp10	ENSDARG00000070272
drosophila_melanogaster	Dredd	FBGN0020381
caenorhabditis_elegans		WBGENE00000417
caenorhabditis_elegans		WBGENE00000819
caenorhabditis_elegans		WBGENE00000820
caenorhabditis_elegans	csp-3	WBGENE00000821

Paralogs (16): CFLAR (ENSG00000003402), CASP8 (ENSG00000064012), PYCARD (ENSG00000103490), CASP14 (ENSG00000105141), CASP2 (ENSG00000106144), CASP9 (ENSG00000132906), CASP1 (ENSG00000137752), CASP5 (ENSG00000137757), CASP6 (ENSG00000138794), CASP3 (ENSG00000164305), CASP7 (ENSG00000165806), PYDC1 (ENSG00000169900), CASP4 (ENSG00000196954), CARD16 (ENSG00000204397), CASP12 (ENSG00000204403), CARD18 (ENSG00000255501)

Protein

Protein identifiers

Caspase-10 — Q92851 (reviewed: Q92851)

Alternative names: Apoptotic protease Mch-4, FAS-associated death domain protein interleukin-1B-converting enzyme 2, ICE-like apoptotic protease 4

All UniProt accessions (6): Q92851, A0A0S2Z3G5, A0A0S2Z3Z5, A0A8Q3SJ84, A0A8Q3WLN0, B4E3T5

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the activation cascade of caspases responsible for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner. May participate in the granzyme B apoptotic pathways. Cleaves and activates effector caspases CASP3, CASP4, CASP6, CASP7, CASP8 and CASP9. Hydrolyzes the small- molecule substrates, Tyr-Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC. Isoform 7 can enhance NF-kappaB activity but promotes only slight apoptosis. Isoform C is proteolytically inactive.

Subunit / interactions. Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 23/17 kDa (p23/17) (depending on the splicing events) and a 12 kDa (p12) subunit. Self-associates. Interacts with FADD and CASP8. Found in a Fas signaling complex consisting of FAS, FADD, CASP8 and CASP10. Interacts with RFFL and RNF34; negatively regulate CASP10 through proteasomal degradation. Interacts with RIOK3.

Tissue specificity. Detectable in most tissues. Lowest expression is seen in brain, kidney, prostate, testis and colon.

Post-translational modifications. Cleavage by granzyme B and autocatalytic activity generate the two active subunits.

Disease relevance. Autoimmune lymphoproliferative syndrome 2A (ALPS2A) [MIM:603909] A disorder of apoptosis that manifests in early childhood and results in the accumulation of autoreactive lymphocytes. It is characterized by non-malignant lymphadenopathy with hepatosplenomegaly, and autoimmune hemolytic anemia, thrombocytopenia and neutropenia. The disease is caused by variants affecting the gene represented in this entry. Familial non-Hodgkin lymphoma (NHL) [MIM:605027] Cancer that starts in cells of the lymph system, which is part of the body’s immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss. The gene represented in this entry is involved in disease pathogenesis. Gastric cancer (GASC) [MIM:613659] A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease. The gene represented in this entry is involved in disease pathogenesis.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the peptidase C14A family.

Isoforms (7)

UniProt ID	Names	Canonical?
Q92851-1	A, 10-A	yes
Q92851-2	B, 10-B, 10-S
Q92851-4	D, 10-D, 10-L
Q92851-3	C, 10-C
Q92851-5	5
Q92851-6	6
Q92851-7	7, 10-G, 10g

RefSeq proteins (7): NP_001193453, NP_001193471, NP_001221, NP_001293012, NP_116756, NP_116758, NP_116759* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001309	Pept_C14_p20	Domain
IPR001875	DED_dom	Domain
IPR002138	Pept_C14_p10	Domain
IPR011029	DEATH-like_dom_sf	Homologous_superfamily
IPR011600	Pept_C14_caspase	Domain
IPR015917	Pept_C14A	Domain
IPR016129	Caspase_his_AS	Active_site
IPR029030	Caspase-like_dom_sf	Homologous_superfamily
IPR033139	Caspase_cys_AS	Active_site
IPR035701	CASP10_DED2	Domain

Pfam: PF00656, PF01335

Enzyme classification (BRENDA):

• EC 3.4.22.63 — caspase-10 (BRENDA: 7 organisms, 41 substrates, 22 inhibitors, 4 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
DEVD-7-AMIDO-4-METHYLCOUMARIN	0.071–0.13	2
ACETYL-VEHD-7-AMIDO-4-METHYLCOUMARIN	0.042	1
YVAD-7-AMIDO-4-METHYLCOUMARIN	0.15	1

UniProt features (34 total): sequence variant 14, splice variant 7, chain 2, sequence conflict 2, domain 2, compositionally biased region 2, active site 2, propeptide 1, mutagenesis site 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92851-F1	69.54	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 358; 401

Mutagenesis-validated functional residues (1):

Position	Phenotype
401	abolishes proteolytic activity.

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases
R-HSA-75157	FasL/ CD95L signaling
R-HSA-75158	TRAIL signaling
R-HSA-933543	NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
R-HSA-162582	Signal Transduction
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-73887	Death Receptor Signaling
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 408 (showing top): REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA, MORF_FLT1, REACTOME_INNATE_IMMUNE_SYSTEM, MORF_MSH3, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, MORF_ESR1, MORF_RAD51L3, LI_WILMS_TUMOR_ANAPLASTIC_DN, GOBP_PROTEIN_MATURATION, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, MURAKAMI_UV_RESPONSE_1HR_UP, GOBP_NEURON_APOPTOTIC_PROCESS, NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_DN, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, PID_P53_DOWNSTREAM_PATHWAY

GO Biological Process (8): proteolysis (GO:0006508), apoptotic process (GO:0006915), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), positive regulation of neuron apoptotic process (GO:0043525), protein maturation (GO:0051604), positive regulation of execution phase of apoptosis (GO:1900119), regulation of apoptotic process (GO:0042981), execution phase of apoptosis (GO:0097194)

GO Molecular Function (7): cysteine-type endopeptidase activity (GO:0004197), ubiquitin protein ligase binding (GO:0031625), death effector domain binding (GO:0035877), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), CD95 death-inducing signaling complex (GO:0031265), ripoptosome (GO:0097342)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Death Receptor Signaling	2
TP53 Regulates Transcription of Cell Death Genes	1
DDX58/IFIH1-mediated induction of interferon-alpha/beta	1
Immune System	1
Innate Immune System	1
RNA Polymerase II Transcription	1
Generic Transcription Pathway	1
Transcriptional Regulation by TP53	1
Gene expression (Transcription)	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein metabolic process	2
execution phase of apoptosis	2
positive regulation of apoptotic process	2
apoptotic process	2
cellular anatomical structure	2
programmed cell death	1
apoptotic signaling pathway	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
gene expression	1
regulation of execution phase of apoptosis	1
regulation of programmed cell death	1
cellular process	1
bleb assembly	1
endopeptidase activity	1
cysteine-type peptidase activity	1
ubiquitin-like protein ligase binding	1
protein domain specific binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
death-inducing signaling complex	1
cytosol	1
catalytic complex	1

Protein interactions and networks

STRING

1054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CASP10	FADD	Q13158	998
CASP10	CASP8	Q14790	985
CASP10	TRADD	Q15628	961
CASP10	RIPK1	Q13546	924
CASP10	CFLAR	O15519	900
CASP10	FASLG	P48023	882
CASP10	FAS	P25445	822
CASP10	TNFRSF10A	O00220	804
CASP10	PARP1	P09874	800
CASP10	CYCS	P00001	797
CASP10	TNFRSF10B	O14763	791
CASP10	TP53	P04637	760
CASP10	RIPK3	Q9Y572	759
CASP10	TNFRSF1A	P19438	755
CASP10	AK2	P54819	749

IntAct

48 interactions, top by confidence:

A	B	Type	Score
FAS	FADD	psi-mi:“MI:0914”(association)	0.960
TNFSF10	TNFRSF10B	psi-mi:“MI:0914”(association)	0.950
CASP10	FADD	psi-mi:“MI:0407”(direct interaction)	0.750
FADD	CASP10	psi-mi:“MI:0407”(direct interaction)	0.750
CASP10	FADD	psi-mi:“MI:0915”(physical association)	0.750
FADD	CASP10	psi-mi:“MI:0915”(physical association)	0.750
CASP8	CFLAR	psi-mi:“MI:0914”(association)	0.740
CASP10	CASP8	psi-mi:“MI:0407”(direct interaction)	0.730
CASP8	CASP10	psi-mi:“MI:0915”(physical association)	0.730
RIOK3	CASP10	psi-mi:“MI:0915”(physical association)	0.720
CASP10	RIOK3	psi-mi:“MI:0915”(physical association)	0.720
CASP10	RIOK3	psi-mi:“MI:0403”(colocalization)	0.720
CASP10	CFLAR	psi-mi:“MI:0914”(association)	0.650
CASP10	CFLAR	psi-mi:“MI:2364”(proximity)	0.650
CFLAR	CASP10	psi-mi:“MI:0915”(physical association)	0.650
CASP10	XIAP	psi-mi:“MI:0915”(physical association)	0.560
XIAP	CASP10	psi-mi:“MI:0915”(physical association)	0.560
TNFRSF10A	TNFRSF10B	psi-mi:“MI:0914”(association)	0.530
CASP10	CASP10	psi-mi:“MI:0407”(direct interaction)	0.440
Dlg4	CASP10	psi-mi:“MI:0407”(direct interaction)	0.440
Fadd	CASP10	psi-mi:“MI:0915”(physical association)	0.400
RIPK1	CASP10	psi-mi:“MI:0915”(physical association)	0.400
MAP3K14	CASP10	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (140): PRDX6 (Reconstituted Complex), FADD (Reconstituted Complex), PRDX6 (Affinity Capture-Western), CASP10 (Reconstituted Complex), CASP10 (Reconstituted Complex), CASP10 (Affinity Capture-Western), PRDX6 (Two-hybrid), CASP10 (PCA), CASP10 (Two-hybrid), CASP10 (Affinity Capture-Western), CASP10 (Affinity Capture-Western), CASP10 (Affinity Capture-Western), CASP10 (Affinity Capture-Western), CASP10 (Affinity Capture-Western), CASP10 (Affinity Capture-Western)

ESM2 similar proteins: A5D7R1, D3ZF92, F1LW30, O00300, O08712, O08727, O14763, O62802, O70458, O70535, O75509, O77736, O95256, P01590, P20334, P20352, P22934, P25118, P25445, P25446, P26897, P30836, P41690, P42703, P51867, P83626, Q07011, Q13478, Q5M9I1, Q61098, Q63199, Q65Z14, Q6UXZ4, Q6X782, Q6X784, Q6X786, Q764M8, Q8K1S2, Q8K5B1, Q90VY2

Diamond homologs: A0A1D5PPP7, F1NV61, O01382, O02002, O08738, O35397, O89110, P29452, P42573, P42574, P55210, P55211, P55212, P55213, P55214, P55866, P70677, P89116, P97864, Q08DY9, Q14790, Q2PFV2, Q3T0P5, Q5IS54, Q5IS99, Q60431, Q8C3Q9, Q8MJC3, Q8MJU1, Q8MKI5, Q92851, Q95ND5, Q9JHX4, G5EBM1, G5ECW5, O15519, O89094, P31944, P42575, P45436

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FADD	up-regulates	CASP10	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Caspase activation via Death Receptors in the presence of ligand	8	304.5×	4e-18
RIPK1-mediated regulated necrosis	10	228.4×	3e-21
Regulation of TNFR1 signaling	5	56.0×	5e-07

GO biological processes:

GO term	Partners	Fold	FDR
extrinsic apoptotic signaling pathway via death domain receptors	8	133.8×	1e-13
extrinsic apoptotic signaling pathway	6	76.6×	6e-09
cellular response to mechanical stimulus	7	63.0×	1e-09
positive regulation of canonical NF-kappaB signal transduction	9	27.2×	1e-09
positive regulation of apoptotic process	9	21.3×	6e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

656 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	1
Uncertain significance	397
Likely benign	155
Benign	62

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
1685600	NM_032977.4(CASP10):c.1504del (p.Gln502fs)	Pathogenic
659600	NC_000002.12:g.(?201228913)(201286614_?)del	Pathogenic
7765	NM_032977.4(CASP10):c.1241C>T (p.Ala414Val)	Pathogenic
7766	NM_032977.4(CASP10):c.769C>T (p.Gln257Ter)	Pathogenic
7767	NM_032977.4(CASP10):c.1042_1043insA (p.Gly348fs)	Pathogenic
3256935	NM_032977.4(CASP10):c.334del (p.Val112fs)	Likely pathogenic

SpliceAI

1691 predictions. Top by Δscore:

Variant	Effect	Δscore
2:201185766:TTCA:T	acceptor_loss	1.0000
2:201185769:A:AG	acceptor_gain	1.0000
2:201185769:A:AT	acceptor_loss	1.0000
2:201185769:AGGCT:A	acceptor_gain	1.0000
2:201185770:G:A	acceptor_loss	1.0000
2:201185770:G:GG	acceptor_gain	1.0000
2:201185770:GGCT:G	acceptor_gain	1.0000
2:201185770:GGCTG:G	acceptor_gain	1.0000
2:201186078:G:GT	donor_gain	1.0000
2:201186078:G:T	donor_gain	1.0000
2:201186124:GGT:G	donor_loss	1.0000
2:201186125:GTGAG:G	donor_loss	1.0000
2:201186126:T:A	donor_loss	1.0000
2:201192979:TGTA:T	acceptor_loss	1.0000
2:201192980:GTAG:G	acceptor_loss	1.0000
2:201192981:TA:T	acceptor_loss	1.0000
2:201192982:A:AC	acceptor_loss	1.0000
2:201192982:A:AG	acceptor_gain	1.0000
2:201192983:G:GA	acceptor_gain	1.0000
2:201192983:GA:G	acceptor_gain	1.0000
2:201192983:GAC:G	acceptor_gain	1.0000
2:201193115:GAAAG:G	donor_gain	1.0000
2:201193118:AG:A	donor_gain	1.0000
2:201193119:GG:G	donor_gain	1.0000
2:201195835:T:G	acceptor_gain	1.0000
2:201195840:A:AG	acceptor_gain	1.0000
2:201195840:AG:A	acceptor_loss	1.0000
2:201195841:G:GC	acceptor_gain	1.0000
2:201195841:GC:G	acceptor_gain	1.0000
2:201195841:GCT:G	acceptor_gain	1.0000

AlphaMissense

3438 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:201208141:T:C	F294L	0.995
2:201208143:T:A	F294L	0.995
2:201208143:T:G	F294L	0.995
2:201209513:A:C	S456R	0.994
2:201209515:C:A	S456R	0.994
2:201209515:C:G	S456R	0.994
2:201208119:T:G	C286W	0.990
2:201209217:C:T	T357I	0.990
2:201209496:G:C	R450P	0.990
2:201208161:A:C	R300S	0.989
2:201208161:A:T	R300S	0.989
2:201208177:G:C	D306H	0.989
2:201209103:T:C	F319S	0.987
2:201209329:A:C	K394N	0.986
2:201209329:A:T	K394N	0.986
2:201208134:C:A	N291K	0.985
2:201208134:C:G	N291K	0.985
2:201209288:T:C	F381L	0.985
2:201209290:C:A	F381L	0.985
2:201209290:C:G	F381L	0.985
2:201209510:G:C	G455R	0.985
2:201208160:G:C	R300T	0.984
2:201208165:G:A	G302R	0.983
2:201208165:G:C	G302R	0.983
2:201209289:T:C	F381S	0.983
2:201185898:T:C	F41L	0.982
2:201185900:T:A	F41L	0.982
2:201185900:T:G	F41L	0.982
2:201209087:T:C	F314L	0.982
2:201209089:C:A	F314L	0.982

dbSNP variants (sampled 300 via entrez): RS1000048412 (2:201205710 A>C), RS1000174546 (2:201216127 G>A), RS1000262725 (2:201225405 T>C,G), RS1000280079 (2:201207564 C>G), RS1000419739 (2:201200832 T>C), RS1000439250 (2:201185722 A>C,G,T), RS1000630458 (2:201205429 C>G), RS1000872273 (2:201185329 G>A), RS1000960935 (2:201221238 A>G), RS1000964443 (2:201214124 T>A), RS1001158423 (2:201199480 C>T), RS1001174606 (2:201187455 G>C,T), RS1001267842 (2:201212681 ATGT>A), RS1001290969 (2:201227429 A>G), RS1001393053 (2:201212053 A>G)

Disease associations

OMIM: gene MIM:601762 | disease phenotypes: MIM:603909, MIM:613659, MIM:605027, MIM:610532, MIM:601859, MIM:607271

GenCC curated gene-disease

Disease	Classification	Inheritance
autoimmune lymphoproliferative syndrome type 2A	Strong	Autosomal dominant
autoimmune lymphoproliferative syndrome	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
autoimmune lymphoproliferative syndrome type 2A	Limited	AD

Mondo (10): autoimmune lymphoproliferative syndrome type 2A (MONDO:0011383), gastric cancer (MONDO:0001056), lymphoma, non-Hodgkin, familial (MONDO:0011508), diffuse midline glioma, H3 K27-altered (MONDO:1060171), hypomyelinating leukodystrophy 5 (MONDO:0012514), autoimmune lymphoproliferative syndrome type 1 (MONDO:0011158), gastric neoplasm (MONDO:0021085), autoimmune lymphoproliferative syndrome type 2B (MONDO:0011804), non-Hodgkin lymphoma (MONDO:0018908), autoimmune lymphoproliferative syndrome (MONDO:0017979)

Orphanet (4): Autoimmune lymphoproliferative syndrome (Orphanet:3261), Hypomyelination-congenital cataract syndrome (Orphanet:85163), Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency (Orphanet:275517), Non-Hodgkin lymphoma (Orphanet:547)

HPO phenotypes

93 total (30 of 93 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000083	Renal insufficiency
HP:0000099	Glomerulonephritis
HP:0000100	Nephrotic syndrome
HP:0000123	Nephritis
HP:0000554	Uveitis
HP:0000854	Thyroid adenoma
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0001025	Urticaria
HP:0001250	Seizure
HP:0001369	Arthritis
HP:0001402	Hepatocellular carcinoma
HP:0001442	Typified by somatic mosaicism
HP:0001744	Splenomegaly
HP:0001789	Hydrops fetalis
HP:0001873	Thrombocytopenia
HP:0001880	Increased total eosinophil count
HP:0001888	Decreased total lymphocyte count
HP:0001890	Autoimmune hemolytic anemia
HP:0001891	Iron deficiency anemia
HP:0001892	Abnormal bleeding
HP:0001904	Autoimmune neutropenia
HP:0001923	Reticulocytosis
HP:0001971	Hypersplenism
HP:0001973	Autoimmune thrombocytopenia
HP:0002113	Pulmonary infiltrates
HP:0002206	Pulmonary fibrosis
HP:0002239	Gastrointestinal hemorrhage
HP:0002240	Hepatomegaly

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002073_6	Chronic lymphocytic leukemia	3.000000e-09
GCST002842_11	Basal cell carcinoma	2.000000e-09
GCST004146_3	Chronic lymphocytic leukemia	5.000000e-11
GCST008724_1	Chronic lymphocytic leukemia or rheumatoid arthritis	7.000000e-09
GCST90002390_462	Mean corpuscular hemoglobin	6.000000e-11
GCST90011898_92	Alanine aminotransferase levels	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D056735	Autoimmune Lymphoproliferative Syndrome	C15.604.515.138; C16.320.089; C20.111.288; C20.683.515.124
D008228	Lymphoma, Non-Hodgkin	C04.557.386.480; C15.604.515.569.480; C20.683.515.761.480
D013274	Stomach Neoplasms	C04.588.274.476.767; C06.301.371.767; C06.405.249.767; C06.405.748.789
C565833	Autoimmune Lymphoproliferative Syndrome, Type IIA (supp.)
C567166	Leukodystrophy, Hypomyelinating, 5 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3831289 (PROTEIN FAMILY), CHEMBL5037 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — C14: Caspase

Binding affinities (BindingDB)

1 measured of 3 human assays (3 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(E,3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-(phenylmethoxycarbonylamino)propanoyl]amino]-2-phenylacetyl]amino]-3-methylbutanoyl]amino]-5-methylsulfonylpent-4-enoic acid	IC50	2000 nM	US-9045524: Selective caspase inhibitors and uses thereof

ChEMBL bioactivities

13 potent at pChembl≥5 of 15 total, top 12 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.92	Ki	12	nM	CHEMBL5723373
7.80	EC50	16	nM	CHEMBL1091826
7.39	IC50	40.4	nM	CHEMBL5715921
6.89	IC50	130	nM	CHEMBL2324339
6.85	IC50	140	nM	CHEMBL5715925
6.62	IC50	240	nM	CHEMBL5715921
6.38	IC50	420	nM	CHEMBL2323967
6.23	IC50	590	nM	CHEMBL2324341
5.70	IC50	2000	nM	CHEMBL3678074
5.57	IC50	2670	nM	CHEMBL2323966
5.48	IC50	3300	nM	CHEMBL2324340
5.30	IC50	5000	nM	GRASSYSTATIN A

PubChem BioAssay actives

7 with measured affinity, of 19 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(4-methoxyphenyl)-N-methyl-1,2,3-benzotriazin-4-amine	1393168: Activation of caspase cascade in human T47D cells using N-(Ac-DEVD)-N’-ethoxycarbonyl-R110 fluorogenic substrate incubated for 48 hrs by fluorescent plate reader based assay	ec50	0.0160	uM
(E,3S)-3-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-5-methylsulfonylpent-4-enoic acid	726060: Inhibition of caspase-10 (unknown origin)	ic50	0.1300	uM
(E,3S)-3-[[(2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-(phenylmethoxycarbonylamino)propanoyl]amino]-3,3-dimethylbutanoyl]azetidine-2-carbonyl]amino]-5-methylsulfonylpent-4-enoic acid	726060: Inhibition of caspase-10 (unknown origin)	ic50	0.4200	uM
(E,3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-(phenylmethoxycarbonylamino)propanoyl]amino]-2-phenylacetyl]amino]-3-methylbutanoyl]amino]-6-ethoxy-6-oxohex-4-enoic acid	726060: Inhibition of caspase-10 (unknown origin)	ic50	0.5900	uM
(E,3S)-3-[[(2S)-1-[(2R)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-5-methylsulfonylpent-4-enoic acid	726060: Inhibition of caspase-10 (unknown origin)	ic50	2.6700	uM
(E,3S)-3-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-3-(1H-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-5-methylsulfonylpent-4-enoic acid	726060: Inhibition of caspase-10 (unknown origin)	ic50	3.3000	uM
methyl (2S)-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-2-[[(3S,4S)-4-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]oxy-3-methylbutanoyl]oxy-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]-methylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate	448868: Inhibition of caspase 10 after 10 to 15 mins by fluorescence assay	ic50	5.0000	uM

CTD chemical–gene interactions

111 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, affects cotreatment, increases expression, decreases expression	5
Arsenic Trioxide	decreases reaction, increases activity, increases expression, affects cotreatment	4
Quercetin	affects reaction, increases activity, increases reaction, increases expression, increases cleavage (+1 more)	4
bisphenol A	decreases expression, increases activity, increases expression	3
Resveratrol	increases reaction, increases expression, increases activity, increases localization, decreases activity (+2 more)	3
trichostatin A	affects reaction, increases activity, increases reaction, affects cotreatment	2
dioscin	increases expression	2
methacrylaldehyde	affects cotreatment, affects expression, increases abundance	2
usnic acid	affects cotreatment, decreases expression, increases expression	2
(+)-JQ1 compound	decreases expression	2
6-OH-BDE-47	decreases expression	2
Acetylcysteine	increases activity, decreases expression, decreases reaction	2
Acrolein	affects cotreatment, affects expression, increases abundance	2
Arsenic	decreases expression, increases abundance, increases expression, affects cotreatment	2
Diclofenac	affects expression, affects cotreatment, increases activity	2
Doxorubicin	increases expression, decreases expression	2
Methotrexate	decreases expression, increases expression	2
Ozone	affects cotreatment, affects expression, increases abundance	2
Paraquat	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Plant Extracts	increases expression	2
Valproic Acid	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
moringin	affects cotreatment, decreases expression	1
TL8-506	affects cotreatment, increases expression	1
beauvericin	increases expression	1
alpha-pinene	affects cotreatment, affects expression, increases abundance	1
propionaldehyde	increases expression	1
sanguinarine	affects cotreatment, increases expression	1
lead acetate	affects cotreatment, increases expression	1

ChEMBL screening assays

22 unique, capped per target: 21 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4199992	Binding	Activation of caspase (unknown origin)	MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. — ACS Med Chem Lett
CHEMBL5723094	Functional	Affinity Biochemical interaction: (enzymatic assay (fluorogenic substrate cleavage)) EUB0002173aAD CASP10	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1LV	Abcam K-562 CASP10 KO	Cancer cell line	Female
CVCL_UQ27	Abcam Jurkat CASP10 KO	Cancer cell line	Male

Clinical trials (associated diseases)

306 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00558155	PHASE4	COMPLETED	The Impact of Immunostimulating Nutrition on the Outcome of Surgery
NCT00576940	PHASE4	COMPLETED	Standard and Immunostimulating Enteral Nutrition in Surgical Patients
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT01038154	PHASE4	UNKNOWN	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
NCT01234272	PHASE4	COMPLETED	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-
NCT01260194	PHASE4	TERMINATED	A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01401075	PHASE4	COMPLETED	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
NCT01471756	PHASE4	COMPLETED	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
NCT01766765	PHASE4	UNKNOWN	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy
NCT01910948	PHASE4	UNKNOWN	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients
NCT01927328	PHASE4	UNKNOWN	Iron Replacement in Oesophagogastric Neoplasia
NCT01962272	PHASE4	COMPLETED	The Effect of Nutritional Counseling for Cancer Patients
NCT01962376	PHASE4	UNKNOWN	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
NCT02047994	PHASE4	RECRUITING	Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
NCT02235246	PHASE4	COMPLETED	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
NCT02366819	PHASE4	SUSPENDED	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02401971	PHASE4	UNKNOWN	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
NCT02458573	PHASE4	COMPLETED	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy
NCT02638584	PHASE4	COMPLETED	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
NCT02776527	PHASE4	UNKNOWN	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03550482	PHASE4	COMPLETED	Oncoxin® and Quality of Life in Cancer Patients
NCT03609892	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03642093	PHASE4	UNKNOWN	HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery
NCT03733639	PHASE4	UNKNOWN	Tisseel® as a Reinforcement of Esophagojejunal Anastomoses
NCT04168346	PHASE4	NOT_YET_RECRUITING	Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer
NCT04209933	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
NCT04591028	PHASE4	WITHDRAWN	A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
NCT04607057	PHASE4	UNKNOWN	Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient
NCT04660123	PHASE4	COMPLETED	A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
NCT04678492	PHASE4	COMPLETED	Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04697186	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05029453	PHASE4	UNKNOWN	Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
NCT05183126	PHASE4	RECRUITING	Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05354856	PHASE4	TERMINATED	The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
NCT05410535	PHASE4	COMPLETED	To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy
NCT05498766	PHASE4	NOT_YET_RECRUITING	Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT05518929	PHASE4	COMPLETED	Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients